Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS: SEPTEMBER ISSUE PUBLISHED
  • SEPTEMBER 2021 Issue has been successfully launched on 1 September 2021.

Abstract

COMPARATIVE STUDY OF ATORVASTATIN 10MG WITH EZETIMIBE 10MG COMBINATION VERSUS ATORVASTATIN 80MG FOR LIPID METABOLISM AND PLEIOTROPIC VASCULAR INFLAMMATORY BIOMARKERS IN DIABETES MELLITUS PATIENTS.

Gune Aryan Rahul*, Meeta Burande, Gune Anita R., Gune Rahul P.,
Burande Amit R.

ABSTRACT

Patients with diabetes have an overall increased risk of cardiovascular disease. Beneficial effect of statin may be due to pleotropic effect when used along with ezetimibe. Aims and objectives of this study were to study the efficacy and safety of 80mg atorvastatin with 10mg atorvastatin and 10mg ezetamibe combination in reduction of lipid biomarkers in uncontrolled dyslipidemia in diabetes patients. The study was conducted after the approval of ICMR-STS committee and institutional ethical committee. 200 Patients were screened out of which 72 volunteers were consulted. 35 of which were selected on basis of inclusion and exclusion criteria. Volunteers were randomised to any of the 2 groups. In-group A, they received atorvastatin 80mg at bedtime for 1 month. In-group B they received atorvastatin 10mg and ezetamibe 10mg at bedtime for 1 month. Our study concludes that combination of Statin and ezetimibe is equipotent to maximum dose of statin at reducing LDL-C but combination shows more reduction in the c-reactive protein levels, suggestive of lesser chances of inflammation. Our results are favourable, further studies may be conducted for evaluation in long term efficacy including reduction in common carotid intima thickness reduction, progression of atherosclerosis as well as evaluation of other specific and extensive vascular markers.

Keywords: Pleotropic inflammatory biomarker, atorvastatin, ezetamibe.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More